Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2462-2469

  Phuong, Loi K ^a   Allen, Cory ^a   Peng, Kah Whye ^a   Giannini, Caterina ^a   Greiner, Suzanne ^a   TenEyck, Cynthia J ^a   Mishra, Prasanna K ^a   Macura, Slobodan I ^a   Russell, Stephen J ^a   Galanis, Evanthia C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; HEMOSIDERIN; MEASLES VACCINE CARCINOEMBRYONIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENETIC ENGINEERING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MEASLES VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TUMOR CELL LINE; TUMOR REGRESSION; ULTRAVIOLET RADIATION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; APOPTOSIS; BRAIN NEOPLASMS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CERCOPITHECUS AETHIOPS; GENETIC ENGINEERING; GLIOBLASTOMA; HUMANS; MEASLES VACCINE; MEASLES VIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; TUMOR CELLS, CULTURED; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037843576     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Greenlee, R., Murray, T., Bolden, S., and Wingo, P. Cancer statistics. CA Cancer J. Clin., 50: 7-33, 2000.
2. Berger, M., Prados, M., and van Gilder, J. Phase II trial of GLI 328 HSV-tk gene therapy in recurrent glioblastoma. Cancer Gene Ther., 4(Suppl.): 542, 1997.
3. Oldfield, E. Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous gancyclovir. Hum. Gene Ther., 4: 39-69, 1993.
4. Rainov, N. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and gancyclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 11: 2389-2401, 2000.
5. Ram, Z., Culver, K., Oshiro, E., et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3: 1354-1361, 1997.
6. Galanis, E., Bateman, A., and Johnson, K. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Ther., 12: 811-821, 2001.
7. Lang, F. F., Fuller, G. N., Prados, M., and Yung, W. A. Preliminary results of a phase I clinical trial of adenovirus-mediated p53 gene therapy for recurrent gliomas: Biological studies. Proc. Am. Soc. Clin. Oncol., 19: 455a, 2000.
8. Wild, T., Malvoisin, E., and Buckland, R. Measles virus: both the hemagglutinin and fusion glycoproteins are required for fusion. J. Gen. Virol., 72(part 2): 439-442, 1991.
9. Tatsuo, H., Ono, N., Tanaka, K., et al. SLAM (CDw150) is a cellular receptor for measles virus. Nature (Lond.), 406: 893-897, 2000.
10. Dorig, R., Marcil, A., Chopra, A., et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell, 75: 295-305, 1993.
11. Naniche, D., Varior-Krishnan, G., Cervoni, F., et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol., 67: 6025-6032, 1993.
12. Jurianz, K., Ziegler, S., Garcia-Schuler, H., et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol, 36: 929-939, 1999.
13. Cutts, F. T., Markowitz, L. E. Successes and failures in measles control. J. Infect. Dis., 170(Suppl. 1): S32-S41, 1994.
14. Grote, D., Russell, S., and Cornu, T. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 97: 3746-3754, 2001.
15. Peng, K. W., Ahmann, G. J., Pham, L., et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood, 98: 2002-2007, 2001.
16. Peng, K. W., TenEyck, C. J., Galanis, E., et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res., 62: 4656-4662, 2002.
17. Yanagi, Y. The cellular receptor for measles virus. Uirusu, 51: 201-208, 2001.
18. Schneider, U., von Messling, V., Devaux, P., et al. Efficiency of measles virus entry and dissemination through different receptors. J. Virol., 76: 7460-7467, 2002.
19. Berinstein, N. L. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J. Clin. Oncol., 20: 2197-2207, 2002.
20. Peng, K. W., Facteau, S., Wegman, T., et al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med., 8: 527-531, 2002.
21. Radecke, F., Spielhofer, P., Schneider, H., et al. Rescue of measles virus from cloned DNA. EMBO J., 14: 5773-5784, 1995.
22. Spearman, C. The method of right and wrong cases without Gauss's formula. Br. J. Psychol., 2: 227-242, 1908.
23. Cathomen, T., Naim, H., and Cattaneo, R. Measles virus with altered envelope protein cytoplasmic tails gain cell fusion competence. J. Virol., 73: 9568-9575, 1998.
24. Dethlefsen, L., Prewitt, J., and Mendelsohn, M. Analysis of tumor group curves. J. Natl. Cancer Inst., 40: 389-405, 1968.
25. Rencher, A. C. Methods of Multivariate Analysis, Ed. 2. New York: John Wiley & Sons, 2002.
26. Mrkic, B., Pavlovic, J., Rulicke, T., et al. Measles virus spread and pathogenesis in genetically modified mice. J. Virol., 72: 7420-7427, 1998.
27. Roscic-Mrkic, B., Schwendener, R. A., Odermatt, B., et al. Roles of macrophages in measles virus infection of genetically modified mice. J. Virol., 75: 3343-3351, 2001.
28. Mrkic, B., Odermatt, B., Klein, M. A., et al. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J. Virol., 74: 1364-1372, 2000.
29. Singh, M., Cattaneo, R., and Billeter, M. A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J. Virol., 73: 4823-4828, 1999.
30. Shand, N., Weber, Mariani, L. et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GL1328 European-Canadian Study Group. Hum. Gene Ther., 29, 10: 2325-2335, 1999.
31. Markert, J., Medlock, M., Rabkin, S., et al. Conditionally replicating herpes simplex virus mutant. G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7: 867-874, 2000.
32. Rampling, R., Cruickshank, G., Papanastassious, V., et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 7: 859-866, 2000.
33. Blasberg, R., and Tjuvajev, J. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q. J. Nucl. Med., 43: 163-169, 1999.
34. Gambhir, S., Herschman, H., Cherry, S., et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia, 2: 118-138, 2000.
35. Bennett, J., Tjuvajev, J., Johnson, P., et al. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat. Med., 7: 859-863, 2001.
36. Jacobs, A., Tjuvajev, J., Dubrovin, M., et al. Positron emission tomography-based imaging of transgene expression mediated by replicating-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vitro. Cancer Res., 61: 2983-2995, 2001.
37. Jacobs, A., Voges, J., Reszka, R., et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet, 358: 727-729, 2001.
38. Tjuvajev, J., Finn, R., Watanabe, K., et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res., 56: 4087-4095, 1996.
39. Esolen, L. M., Park, S. W., Hardwick, J. M., et al. Apoptosis as a cause of death in measles virus-infected cells. J. Virol., 69: 3955-3958, 1995.
40. Albrecht, P., Shabo, A., Burns, R., et al. Experimental measles encephalitis in normal and cyclophosphamide treated rhesus monkeys. J Infect. Dis., 126: 154-161, 1972.
41. Buynak, E. B., Peck, H. M., Creamer, V. M. D., Goldner, H., and Hilleman, M. R. Differentiation of virulent from avirulent measles strains. Am. J. Dis. Child, 103: 460-473, 1962.
42. Enders, J. F., Katz, S. L., Milovanovic, M. V., and Holloway, A. Studies of an attenuated measles-virus vaccine. Development and preparation of the vaccine: Technics for assay of effects of vaccination. N. Engl. J. Med., 263: 153-159, 1960.